German radiopharmaceutical firm ITM Isotopen Technologies said a European Medicines Agency (EMA) committee has recommended marketing authorization for the company's EndolucinBeta radiopharmaceutical precursor.
EndolucinBeta (lutetium chloride-177) is utilized in radionuclide therapy for precision oncology, radiolabeling carrier molecules such as peptides, monoclonal antibodies, vitamins, or other substrates, ITM Isotopen said. The positive opinion on ITM's marketing authorization application was provided by the EMA's Committee for Medicinal Products for Human Use.
